Supernus Pharmaceuticals, Inc. : Investors : Press Releases : Shire Laboratories receives US Patent # 6,384,020 on rapid immediate release oral dosage form

This press release was released prior to the formation of Supernus Pharmaceuticals.

Press Release

FOR IMMEDIATE RELEASE May 7, 2002	CONTACT: Woody Bryan, PhD. Tel +1 301 838 2681

Shire Laboratories receives US Patent # 6,384,020 on rapid immediate release oral dosage form

ROCKVILLE, MD - (7 May, 2002) - Shire Laboratories, Inc. announced today that the US Patent and Trademark Office has issued US Patent # 6,384,020 for the company's rapid immediate release oral dosage form.

# # #

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. The statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties, including but not limited to, risks associated with the inherent uncertainty of pharmaceutical research, product development and commercialization, the impact of competitive products, patents, and other risks and uncertainties, including those detailed from time to time in periodic reports, including the F-4 Prospectus and the Annual Report filed on Form 20-F with the Securities and Exchange Commission.